Form 4: Director Amy McKee Acquires BIOCRYST PHARMACEUTICALS Shares

BIOCRYST PHARMACEUTICALS Director Amy E McKee acquired 676 shares of common stock at $8.31 per share as part of her board retainer.

Summary

• Amy E McKee, a Director of BIOCRYST PHARMACEUTICALS INC (BCRX), acquired 676 shares of common stock.
• The transaction occurred on August 29, 2025, at a price of $8.31 per share.
• These shares were issued in lieu of 50% of her quarterly cash Board Member retainer, which is $11,250.
• Following this transaction, Ms. McKee directly beneficially owns 41,007 shares of BCRX common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine insider acquisition as part of compensation, indicating continued director alignment and no negative signals. The future transaction date is unusual but likely a reporting anomaly or a pre-scheduled event.

Positives

• Director Amy E McKee increased her direct beneficial ownership in BIOCRYST PHARMACEUTICALS INC by 676 shares, demonstrating continued alignment with shareholder interests.
• The acquisition of shares as part of the board retainer indicates a non-cash compensation component, potentially conserving company cash.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, reflecting a director's compensation structure. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across various industries, including biotechnology and pharmaceuticals, aligning director incentives with shareholder value.
• The specific value of the retainer and the proportion paid in stock (50%) would typically be benchmarked against peer companies like Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX) to assess competitiveness and governance practices, though this filing does not provide such a comparison.

Related Party Transactions

• The acquisition of 676 shares by Director Amy E McKee as part of her quarterly board member retainer constitutes a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The transaction increases Director Amy E McKee's direct equity ownership, further aligning her financial interests with those of common shareholders.
• Creditors: The decision to pay 50% of the board retainer in stock rather than entirely in cash may slightly conserve the company's cash reserves, which could be viewed positively by creditors.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director received shares as part of her compensation. While it indicates continued alignment of interests, it does not provide new fundamental information about the company's performance, strategy, or financial health that would warrant a change in investment recommendation. Investors should consider this a neutral event in the context of their broader analysis of BCRX.

Keywords

BIOCRYST PHARMACEUTICALS, BCRX, Amy E McKee, Insider Trading, Form 4, Stock Acquisition, Director Compensation, Equity Compensation